GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entera Bio Ltd (FRA:5DT) » Definitions » Short-Term Debt

Entera Bio (FRA:5DT) Short-Term Debt : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Entera Bio Short-Term Debt?

Entera Bio's Short-Term Debt for the quarter that ended in Mar. 2024 was €0.00 Mil.


Entera Bio Short-Term Debt Historical Data

The historical data trend for Entera Bio's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entera Bio Short-Term Debt Chart

Entera Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only - - - - -

Entera Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Entera Bio Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Entera Bio Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Entera Bio's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Entera Bio (FRA:5DT) Business Description

Traded in Other Exchanges
Address
Minrav Building - Fifth Floor, Kiryat Hadassah, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Entera Bio (FRA:5DT) Headlines

No Headlines